Sunday, June 4, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

The Illumina Example: DTRA as a Catalyst for Biotech Growth

by Global Biodefense Staff
December 11, 2012
DTRA Counter-WMD Research

A recent article published by the Department of Defense highlights the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department (DTRA CB) contributions to the economy and technology advancements by providing the spark companies need to further development by the deeper pockets of venture capital.

The article cites the development of the Illumina, Inc. product line for genotyping, gene expression, copy-number variation and methylation analyses. “That started with early funding of work at Tufts University using a bead array concept as an analysis tool. Later, the bead arrays were diversified in their application to vapor sensing, which was funded through the Defense Advanced Research Projects Agency’s (DARPA) ‘Dog’s Nose program,’ an advanced, field-portable system for detecting land mines.”

The full line of Illumina products is now in wide use by not only the researchers at the Department of Defense, but at many other federal laboratories and major genome centers around the world.

Nels Olson, Ph.D., DTRA CB’s thrust coordinator for Sensing and Reporting and the Diagnostics Division’s senior advisor on biotechnology reagents, instruments and disposables, explains that while DTRA CB investments might be just a few million dollars, venture capitalists see it as a vetting process that proves the concept and encourages them to make the much larger investments. The government benefits when these innovations reach commercialization levels and are able to be purchased to protect warfighters in the field.

“DTRA can come up with some money to get the research going,” says Olson. “But it’s the $100-200 million investments by private capital after we show the idea will work that get the factories built and the technology cranked out at a viable cost to consumers, including DTRA.”

Read more at DVIDS: DTRA-CB initial investment money helps grow development

Tags: Defense Threat Reduction Agency

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC